Norovirus
7
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
14 treatments under study, led by Cdi988
Research Leaders
5 sponsors active, led by Takeda
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (7)
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus
Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults
Recombinant, Bivalent, Norovirus Vaccine Study
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Phase 1 Norwalk Vaccine Study
Research Network
Common Treatments
- Cdi9881
- 09 Sodium Chloride Saline1
- Adjuvantexcipients1
- Norovirus Gi1gii4 Bivalent Vlp Vaccine1
- Norovirus Gi4 Gii4 Bivalent Vlp Vaccine 100 Μg1
Active Sponsors
- Takeda4
- University Hospital, Ghent1
- LigoCyte Pharmaceuticals, Inc.1
- Icon Genetics GmbH1
- Cocrystal Pharma, Inc.1
Top Investigators
University of Rochester
Hope Clinic of the Emory Vaccine Center
Related Conditions
- Healthy Participants1
- Healthy Volunteers1